8329 Stock Overview
Engages in the research and development, manufacturing, and selling of medicines and medical devices in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shenzhen Neptunus Interlong Bio-technique Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.16 |
| 52 Week High | HK$0.18 |
| 52 Week Low | HK$0.12 |
| Beta | 0.20 |
| 11 Month Change | 23.44% |
| 3 Month Change | 18.80% |
| 1 Year Change | -3.07% |
| 33 Year Change | -34.17% |
| 5 Year Change | -39.23% |
| Change since IPO | -56.71% |
Recent News & Updates
Recent updates
Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings
Sep 05
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings
Apr 19These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely
Oct 03Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?
Mar 29We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt
Sep 28A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
Aug 18Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?
Jun 06Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?
Dec 15Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.
Dec 29Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly
Nov 24Shareholder Returns
| 8329 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 14.5% | 4.2% | 0.4% |
| 1Y | -3.1% | 29.7% | 18.4% |
Return vs Industry: 8329 underperformed the Hong Kong Pharmaceuticals industry which returned 37.7% over the past year.
Return vs Market: 8329 underperformed the Hong Kong Market which returned 30.6% over the past year.
Price Volatility
| 8329 volatility | |
|---|---|
| 8329 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in HK Market | 18.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 8329 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8329's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,471 | n/a | www.interlong.com |
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, and selling of medicines and medical devices in the People’s Republic of China. It offers medicines for various therapeutic areas, including oncology, cardiovascular system, respiratory system, digestive system, and mental disorders. The company is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology business.
Shenzhen Neptunus Interlong Bio-technique Company Limited Fundamentals Summary
| 8329 fundamental statistics | |
|---|---|
| Market cap | HK$265.12m |
| Earnings (TTM) | HK$35.44m |
| Revenue (TTM) | HK$1.16b |
7.5x
P/E Ratio0.2x
P/S RatioIs 8329 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8329 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.05b |
| Cost of Revenue | CN¥658.52m |
| Gross Profit | CN¥395.31m |
| Other Expenses | CN¥363.16m |
| Earnings | CN¥32.15m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 37.51% |
| Net Profit Margin | 3.05% |
| Debt/Equity Ratio | 8.5% |
How did 8329 perform over the long term?
See historical performance and comparison